Search Filters
One of the aims of the UKRMP in overcoming the barriers to regenerative medicine being used in mainstream therapies is the development of new tools reagents, protocols. Further details of the activities and progress across the Hubs and Platform can be found through the following publications
2023
Epigenetic dynamics during capacitation of naïve human pluripotent stem cells
Agostinho de Sousa J, Wong CW, Dunkel I, Owens T, Voigt P, Hodgson A, Baker D, Schulz EG, Reik W, Smith A, Rostovskaya M, von Meyenn F.Sci Adv. 2023 Sep 29;9(39):eadg1936. doi: 10.1126/sciadv.adg1936. Epub 2023 Sep 29.
Pluripotent stem cells and engineered cells
ISSCR standards for the use of human stem cells in basic research.
Ludwig TE, Andrews PW, Barbaric I, Benvenisty N, Bhattacharyya A, Crook JM, Daheron LM, Draper JS, Healy LE, Huch M, Inamdar MS, Jensen KB, Kurtz A, Lancaster MA, Liberali P, Lutolf MP, Mummery CL, Pera MF, Sato Y, Shimasaki N, and Mosher JTStem Cell Reports, 18:9, p1744-1752, Sep 12, 2023.
Pluripotent stem cells and engineered cells
Lessons learnt, and still to learn, in first in human stem cell trials.
Barker, R.A., Carpenter, M., Jamieson, C.H.M., Murry, C.E., Pellegrini, G., Rao, R.C., & Song, J.Stem Cell Reports, 18:8, p1599-1609, Aug 08 2023. Doi:https://doi.org/10.1016/j.stemcr.2022.11.019
Pluripotent stem cells and engineered cells
Highly efficient platelet generation in lung vasculature reproduced by microfluidics.
Zhao, X., Alibhai, D., Walsh, T.G., Tarassova, N., Englert, M., Birol, S.Z., Li, Y., Williams, C.M., Neal, C.R., Burkard, P., Cross, S.J., Aitken, E.W., Waller, A.K., Ballester Beltrán, J., Gunning, P.W., Hardeman, E.C., Agbani, E.O., Nieswandt, B., Hers, I., Ghevaert, C., & Poole, A.WNat Commun 14, 4026 (2023). https://doi.org/10.1038/s41467-023-39598-9
Blood – Platelets (Megakaryocytes)
, Pluripotent stem cells and engineered cells
The isochromosome 20q abnormality of pluripotent cells interrupts germ layer differentiation.
Vitillo L, Anjum F, Hewitt Z, Stavish D, Laing O, Baker D, Barbaric I, Coffey PStem Cell Reports, Volume 18, Issue 3, 782 - 797. DOI: https://doi.org/10.1016/j.stemcr.2023.01.007
Pluripotent stem cells and engineered cells
Engineered neural tissue made using hydrogels derived from decellularised tissues for the regeneration of peripheral nerves
S. C. Kellaway, V. Roberton, J. N. Jones, R. Loczenski, J. B. Phillips, L. J. WhiteDOI: 10.1016/j.actbio.2022.12.003
Engineered neural tissue (EngNT) promotes in vivo axonal regeneration. Decellularised materials (dECM) are complex biologic scaffolds that can improve the cellular environment and also encourage positive tissue remodelling in vivo. We hypothesised that we could incorporate a hydrogel derived from a decellularised tissue (dECMh) into EngNT, thereby providing an alternative to the currently used purified collagen I hydrogel for the first time. Decellularisation was carried out on bone (B-ECM), liver (LIV-ECM), and small intestinal (SIS-ECM) tissues and the resultant dECM was biochemically and mechanically characterised. dECMh differed in mechanical and biochemical properties that likely had an effect on Schwann cell behaviour observed in metabolic activity and contraction profiles. Cellular alignment was observed in tethered moulds within the B-ECM and SIS-ECM derived hydrogels only. No difference was observed in dorsal root ganglia (DRG) neurite extension between the dECMh groups and collagen I groups when applied as a coverslip coating, however, when DRG were seeded atop EngNT constructs, only the B-ECM derived EngNT performed similarly to collagen I derived EngNT. B-ECM EngNT further exhibited similar axonal regeneration to collagen I EngNT in a 10 mm gap rat sciatic nerve injury model after 4 weeks. Our results have shown that various dECMh can be utilised to produce EngNT that can promote neurite extension in vitro and axonal regeneration in vivo.
Liver
, Smart Materials
Peptide-protein co-assemblies into hierarchical and bioactive tubular membranes
A. Majkowska, K.E. Inostroza-Brito, M. Gonzalez, C. Redondo-Gomez, A. Rice, J.C. Rodriguez-Cabello, A.E. Del Rio Hernandez, A MataDOI:10.1021/acs.biomac.2c01095
Multicomponent self-assembly offers opportunities for the design of complex and functional biomaterials with tunable properties. Here, we demonstrate how minor modifications in the molecular structures of peptide amphiphiles (PAs) and elastin-like recombinamers (ELs) can be used to generate coassembling tubular membranes with distinct structures, properties, and bioactivity. First, by introducing minor modifications in the charge density of PA molecules (PAK2, PAK3, PAK4), different diffusion-reaction processes can be triggered, resulting in distinct membrane microstructures. Second, by combining different types of these PAs prior to their coassembly with ELs, further modifications can be achieved, tuning the structures and properties of the tubular membranes. Finally, by introducing the cell adhesive peptide RGDS in either the PA or EL molecules, it is possible to harness the different diffusion-reaction processes to generate tubular membranes with distinct bioactivities. The study demonstrates the possibility to trigger and achieve minor but crucial differences in coassembling processes and tune material structure and bioactivity. The study demonstrates the possibility to use minor, yet crucial, differences in coassembling processes to tune material structure and bioactivity.
Musculoskeletal
, Smart Materials
Material-driven fibronectin and vitronectin assembly enhances BMP-2 presentation and osteogenesis
Y. Xiao, H. Donnelly, M. Sprott, J. Luo, V. Jayawarna, L. Lemgruber, P. M. Tsimbouri, R.M.D. Meek, M. Salmeron-Sanchez, M. J. DalbyDOI: 10.1016/j.mtbio.2022.100367
Mesenchymal stem cell (MSC)-based tissue engineering strategies are of interest in the field of bone tissue regenerative medicine. MSCs are commonly investigated in combination with growth factors (GFs) and biomaterials to provide a regenerative environment for the cells. However, optimizing how biomaterials interact with MSCs and efficiently deliver GFs, remains a challenge. Here, via plasma polymerization, tissue culture plates are coated with a layer of poly (ethyl acrylate) (PEA), which is able to spontaneously permit fibronectin (FN) to form fibrillar nanonetworks. However, vitronectin (VN), another important extracellular matrix (ECM) protein forms multimeric globules on the polymer, thus not displaying functional groups to cells. Interestingly, when FN and VN are co-absorbed onto PEA surfaces, VN can be entrapped within the FN fibrillar nanonetwork in the monomeric form providing a heterogeneous, open ECM network. The combination of FN and VN promote MSC adhesion and leads to enhanced GF binding; here we demonstrate this with bone morphogenetic protein-2 (BMP2). Moreover, MSC differentiation into osteoblasts is enhanced, with elevated expression of osteopontin (OPN) and osteocalcin (OCN) quantified by immunostaining, and increased mineralization observed by von Kossa staining. Osteogenic intracellular signalling is also induced, with increased activity in the SMAD pathway. The study emphasizes the need of recapitulating the complexity of native ECM to achieve optimal cell-material interactions.
Musculoskeletal
, Smart Materials
STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity
E.L. Dane, A. Belessiotis-Richards, C. Backlund, J. Wang, K. Hidaka, L.E. Milling, S. Bhagchandani, M.B. Melo, S. Wu, N. Li, N. Donahue, K. Ni, L. Ma, M. Okaniwa, M.M. Stevens, A. Alexander-Katz, D.J. IrvineDOI: 10.1038/s41563-022-01251-z
Activation of the innate immune STimulator of INterferon Genes (STING) pathway potentiates antitumour immunity, but systemic delivery of STING agonists to tumours is challenging. We conjugated STING-activating cyclic dinucleotides (CDNs) to PEGylated lipids (CDN-PEG-lipids; PEG, polyethylene glycol) via a cleavable linker and incorporated them into lipid nanodiscs (LNDs), which are discoid nanoparticles formed by self-assembly. Compared to state-of-the-art liposomes, intravenously administered LNDs carrying CDN-PEG-lipid (LND-CDNs) exhibited more efficient penetration of tumours, exposing the majority of tumour cells to STING agonist. A single dose of LND-CDNs induced rejection of established tumours, coincident with immune memory against tumour rechallenge. Although CDNs were not directly tumoricidal, LND-CDN uptake by cancer cells correlated with robust T-cell activation by promoting CDN and tumour antigen co-localization in dendritic cells. LNDs thus appear promising as a vehicle for robust delivery of compounds throughout solid tumours, which can be exploited for enhanced immunotherapy.
Smart Materials
Polysaccharide-Polyplex Nanofilm Coatings Enhance Nanoneedle-Based Gene Delivery and Transfection Efficiency
D. Hachim, J. Zhao, J. Bhankharia, R. Nuñez-Toldra, L. Brito, H. Seong, M. Becce, L. Ouyang, C.L. Grigsby, S.G. Higgins, C.M. Terracciano, M.M. StevensDOI: 10.1002/smll.202202303
Non-viral vectors represent versatile and immunologically safer alternatives for nucleic acid delivery. Nanoneedles and high-aspect ratio nanostructures are unconventional but interesting delivery systems, in which delivery is mediated by surface interactions. Herein, nanoneedles are synergistically combined with polysaccharide-polyplex nanofilms and enhanced transfection efficiency is observed, compared to polyplexes in suspension. Different polyplex-polyelectrolyte nanofilm combinations are assessed and it is found that transfection efficiency is enhanced when using polysaccharide-based polyanions, rather than being only specific for hyaluronic acid, as suggested in earlier studies. Moreover, results show that enhanced transfection is not mediated by interactions with the CD44 receptor, previously hypothesized as a major mechanism mediating enhancement via hyaluronate. In cardiac tissue, nanoneedles are shown to increase the transfection efficiency of nanofilms compared to flat substrates; while in vitro, high transfection efficiencies are observed in nanostructures where cells present large interfacing areas with the substrate. The results of this study demonstrate that surface-mediated transfection using this system is efficient and safe, requiring amounts of nucleic acid with an order of magnitude lower than standard culture transfection. These findings expand the spectrum of possible polyelectrolyte combinations that can be used for the development of suitable non-viral vectors for exploration in further clinical trials.
Smart Materials
Tissue Engineering Cartilage with Deep Zone Cytoarchitecture by High-Resolution Acoustic Cell Patterning
J.P.K. Armstrong, E. Pchelintseva, S. Treumuth, C. Campanella, C. Meinert, T.J. Klein, D.W. Hutmacher, B.W. Drinkwater, M.M. StevensDOI: 10.1002/adhm.202200481
The ultimate objective of tissue engineering is to fabricate artificial living constructs with a structural organization and function that faithfully resembles their native tissue counterparts. For example, the deep zone of articular cartilage possesses a distinctive anisotropic architecture with chondrocytes organized in aligned arrays ≈1–2 cells wide, features that are oriented parallel to surrounding extracellular matrix fibers and orthogonal to the underlying subchondral bone. Although there are major advances in fabricating custom tissue architectures, it remains a significant technical challenge to precisely recreate such fine cellular features in vitro. Here, it is shown that ultrasound standing waves can be used to remotely organize living chondrocytes into high-resolution anisotropic arrays, distributed throughout the full volume of agarose hydrogels. It is demonstrated that this cytoarchitecture is maintained throughout a five-week course of in vitro tissue engineering, producing hyaline cartilage with cellular and extracellular matrix organization analogous to the deep zone of native articular cartilage. It is anticipated that this acoustic cell patterning method will provide unprecedented opportunities to interrogate in vitro the contribution of chondrocyte organization to the development of aligned extracellular matrix fibers, and ultimately, the design of new mechanically anisotropic tissue grafts for articular cartilage regeneration.
Musculoskeletal
, Smart Materials
Gelatin Methacryloyl Hydrogels for Musculoskeletal Tissue Regeneration
Y. Kim, J. Dawson, R.O.C. Oreffo, Y. Tabata, D. Kumar, C. Aparicio, I. MutrejaDOI: 10.3390/bioengineering9070332
Musculoskeletal disorders are a significant burden on the global economy and public health. Hydrogels have significant potential for enhancing the repair of damaged and injured musculoskeletal tissues as cell or drug delivery systems. Hydrogels have unique physicochemical properties which make them promising platforms for controlling cell functions. Gelatin methacryloyl (GelMA) hydrogel in particular has been extensively investigated as a promising biomaterial due to its tuneable and beneficial properties and has been widely used in different biomedical applications. In this review, a detailed overview of GelMA synthesis, hydrogel design and applications in regenerative medicine is provided. After summarising recent progress in hydrogels more broadly, we highlight recent advances of GelMA hydrogels in the emerging fields of musculoskeletal drug delivery, involving therapeutic drugs (e.g., growth factors, antimicrobial molecules, immunomodulatory drugs and cells), delivery approaches (e.g., single-, dual-release system), and material design (e.g., addition of organic or inorganic materials, 3D printing). The review concludes with future perspectives and associated challenges for developing local drug delivery for musculoskeletal applications.
Musculoskeletal
, Smart Materials
Modelling skeletal pain harnessing tissue engineering
L. Iafrate, M. Benedetti, S. Donsante, A. Rosa, A. Corsi, R.O.C. Oreffo, M. Riminucci, G. Ruocco, C. Scognamiglio, G. CidonioDOI: 10.1007/s44164-022-00028-7
Bone pain typically occurs immediately following skeletal damage with mechanical distortion or rupture of nociceptive fibres. The pain mechanism is also associated with chronic pain conditions where the healing process is impaired. Any load impacting on the area of the fractured bone will stimulate the nociceptive response, necessitating rapid clinical intervention to relieve pain associated with the bone damage and appropriate mitigation of any processes involved with the loss of bone mass, muscle, and mobility and to prevent death. The following review has examined the mechanisms of pain associated with trauma or cancer-related skeletal damage focusing on new approaches for the development of innovative therapeutic interventions. In particular, the review highlights tissue engineering approaches that offer considerable promise in the application of functional biomimetic fabrication of bone and nerve tissues. The strategic combination of bone and nerve tissue engineered models provides significant potential to develop a new class of in vitro platforms, capable of replacing in vivo models and testing the safety and efficacy of novel drug treatments aimed at the resolution of bone-associated pain. To date, the field of bone pain research has centred on animal models, with a paucity of data correlating to the human physiological response. This review explores the evident gap in pain drug development research and suggests a step change in approach to harness tissue engineering technologies to recapitulate the complex pathophysiological environment of the damaged bone tissue enabling evaluation of the associated pain-mimicking mechanism with significant therapeutic potential therein for improved patient quality of life.
Musculoskeletal
, Smart Materials
Advancing Our Understanding of the Chronically Denervated Schwann Cell: A Potential Therapeutic Target?
L. McMorrow, A. Kosalko, D. Robinson, A. Saiani, A. J. ReidDOI: 10.3390/biom12081128
Outcomes for patients following major peripheral nerve injury are extremely poor. Despite advanced microsurgical techniques, the recovery of function is limited by an inherently slow rate of axonal regeneration. In particular, a time-dependent deterioration in the ability of the distal stump to support axonal growth is a major determinant to the failure of reinnervation. Schwann cells (SC) are crucial in the orchestration of nerve regeneration; their plasticity permits the adoption of a repair phenotype following nerve injury. The repair SC modulates the initial immune response, directs myelin clearance, provides neurotrophic support and remodels the distal nerve. These functions are critical for regeneration; yet the repair phenotype is unstable in the setting of chronic denervation. This phenotypic instability accounts for the deteriorating regenerative support offered by the distal nerve stump. Over the past 10 years, our understanding of the cellular machinery behind this repair phenotype, in particular the role of c-Jun, has increased exponentially, creating opportunities for therapeutic intervention. This review will cover the activation of the repair phenotype in SC, the effects of chronic denervation on SC and current strategies to 'hack' these cellular pathways toward supporting more prolonged periods of neural regeneration.
Smart Materials
Rapid fabrication and screening of tailored functional 3D biomaterials: Validation in bone tissue repair – Part II
A. Conde-Gonzalez, M. Glinka, D. Dutta, R. Wallace, A. Callanan, R.O.C. Oreffo, M. BradleyDOI:10.1016/j.bioadv.2022.213250
Regenerative medicine strategies place increasingly sophisticated demands on 3D biomaterials to promote tissue formation at sites where tissue would otherwise not form. Ideally, the discovery/fabrication of the 3D scaffolds needs to be high-throughput and uniform to ensure quick and in-depth analysis in order to pinpoint appropriate chemical and mechanical properties of a biomaterial. Herein we present a versatile technique to screen new potential biocompatible acrylate-based 3D scaffolds with the ultimate aim of application in tissue repair. As part of this process, we identified an acrylate-based 3D porous scaffold that promoted cell proliferation followed by accelerated tissue formation, pre-requisites for tissue repair. Scaffolds were fabricated by a facile freeze-casting and an in-situ photo-polymerization route, embracing a high-throughput synthesis, screening and characterization protocol. The current studies demonstrate the dependence of cellular growth and vascularization on the porosity and intrinsic chemical nature of the scaffolds, with tuneable 3D scaffolds generated with large, interconnected pores suitable for cellular growth applied to skeletal reparation. Our studies showed increased cell proliferation, collagen and ALP expression, while chorioallantoic membrane assays indicated biocompatibility and demonstrated the angiogenic nature of the scaffolds. VEGRF2 expression in vivo observed throughout the 3D scaffolds in the absence of growth factor supplementation demonstrates a potential for angiogenesis. This novel platform provides an innovative approach to 3D scanning of synthetic biomaterials for tissue regeneration.
Musculoskeletal
, Smart Materials
Challenges in the clinical advancement of cell therapies for Parkinson’s disease.
Skidmore, S., Barker, R.A.Nat. Biomed. Eng (2023). https://doi.org/10.1038/s41551-022-00987-y
Parkinson’s disease
, Pluripotent stem cells and engineered cells
2022
Current insights into the bone marrow niche: From biology in vivo to bioengineering ex vivo
Y. Xiao, C.S. McGuinness, W.S. Doherty-Boyd, M. Salmeron-Sanchez, H. Donnelly, M.J. DalbyBiomaterials, 2022, PMID: 35580474. https://doi.org/10.1016/j.biomaterials.2022.121568
Musculoskeletal
, Smart Materials
Living Biointerfaces for the Maintenance of Mesenchymal Stem Cell Phenotypes
M. Petaroudi, A. Rodrigo-Navarro, O. Dobre, M. J. Dalby, M. Salmeron-SanchezAdvanced Functional Materials, 2022, https://doi.org/10.1002/adfm.202203352
Musculoskeletal
, Smart Materials
From hurdle to springboard: The macrophage as target in biomaterial-based bone regeneration strategies
Y.H. Kim, R.O.C. Oreffo, J.I. DawsonBone, 2022, Jun;159:116389. https://doi.org/10.1016/j.bone.2022.116389
Musculoskeletal
, Smart Materials
Mineralizing coating on 3D printed scaffolds for enhanced osseo-integration
A. Hasan, R.Bagnol, R. Owen, A. Latif, H.M. Rostam, S. Elsharkawy, F. Rose, J.C. Rodriguez-Cabello, A.M. Ghaemmaghami, D. Eglin, and A. MataFrontiers in Bioengineering and Biotechnology, 2022, p.810. https://doi.org/10.3389/fbioe.2022.836386
Musculoskeletal
, Smart Materials
Rational design of hydrogels for immunomodulation
W. Bu, Y. Wu, A.M. Ghaemmaghami, H. Sun, A. MataRegenerative Biomaterials, 2022, https://doi.org/10.1093/rb/rbac009.
Smart Materials
Embracing complexity in biomaterials design
H.S. Azevedo and A. Mata ABiomaterials and Biosystems, 2022, https://doi.org/10.1016/j.bbiosy.2022.100039
Smart Materials
Exploiting the fundamental of biological organization for the advancement of biofabrication
J. Hill, R. Wildman, A. MataCurrent Opinion in Biotechnology, 2022, https://doi.org/10.1016/j.copbio.2021.10.016
Smart Materials
Disinfector-assisted low temperature reduced graphene oxide-protein surgical dressing for the postoperative photothermal treatment of melanoma
Y. Wu, J. Yang, A. van Teijlingen, A. Berardo, I. Corridori, J. Feng, J. Xu, M.M. Titirici, J.C. Rodriguez-Cabello, N.M. Pugno, J. Sun, W. Wang, A. MataAdvanced Functional Materials, 2022, https://doi.org/10.1002/adfm.202205802
Smart Materials
Self-assembling, peptide hydrogels as functional tools to tackle intervertebral disc degeneration
C. Ligorio, J.A. Hoyland, A. SaianiGels, 2022, 8(4):211, https://doi.org/10.3390/gels8040211
Smart Materials
Acidic and basic self-assembling peptide and peptide-graphene oxide hydrogels: characterisation and effect on encapsulated nucleus pulposus cells
C. Ligorio, A. Vijayaraghavan, J.A. Hoyland, A. SaianiActa Biomaterialia, 2022,143: 145-158, https://doi.org/10.1016/j.actbio.2022.02.022
Smart Materials
In vitro and in vivo investigation of a zonal microstructured scaffold for osteochondral defect repair
J.A.M. Steele, A.C. Moore, J.S. Pierre, …, M.M. StevensBiomaterials, 2022, 286:121548, https://doi.org/10.1016/j.biomaterials.2022.121548
Smart Materials
Design and clinical application of injectable hydrogels for musculoskeletal therapy
Ø. Øvrebø, G. Perale, J.P. Wojciechowski, C. Echalier, J.R.T. Jeffers, M.M. Stevens, H.J. Haugen, F. RossiBioengineering and Translational Medicine, 2022, ISSN:2380-6761f, https://doi.org/10.1002/btm2.10295
Smart Materials
Tunable Microgel-Templated Porogel (MTP) Bioink for 3D Bioprinting Applications
L. Ouyang, J.P. Wojciechowski, J. Tang, Y. Guo, M.M. StevensAdvanced Healthcare Materials, 2022, ISSN:2192-2640, https://doi.org/10.1002/adhm.202200027
Smart Materials
Modeling the tumor microenvironment of ovarian cancer: the application of self-assembling biomaterials
A.K. Mendoza-Martinez, D. Loessner, A. Mata, H.S. AzevedoCancers, 2022, https://doi.org/10.3390/cancers13225745
Smart Materials
Exploiting the fundamentals of biological organization for the advancement of biofabrication
J. Hill, R. Wildman, A. MataCurrent Opinion in Biotechnology, 2022, https://doi.org/10.1016/j.copbio.2021.10.016
Smart Materials
A reference induced pluripotent stem cell line for large-scale collaborative studies
Pantazis C, Yang A, Lara E, McDonough J, Blauwendraat C, Peng L, Oguro H, Zou J, Sebesta D, Pratt G, Cross E, Blockwick J, Buxton P, Kinner-Bibeau L, Medura C, Tompkins C, Hughes S, Santiana M, Faghri F, Nalls M, Vitale D, Qi Y, Ramos D, Anderson K, Stadler J, Narayan P, Papademetriou J, Reilly L, Nelson M, Aggarwal S, Rosen L, Kirwan P, Pisupati V, Coon S, Scholz S, Coccia E, Sarrafha L, Ahfeldt T, Funes S, Bosco D, Beccari M, Cleveland D, Zanellati M, Basundra R, Deshmukh M, Cohen S, Nevin Z, Matia M, Van Lent J, Timmerman V, Conklin B, Dou D, Holzbaur E, Li E, Rose I, Kampmann M, Priebe T, Öttl M, Dong J, van der Kant R, Erlebach L, Welzer M, Kronenberg-Versteeg D, Abu-Bonsrah D, Parish C, Raman M, Heinrich L, Schüle B, Aristoy C, Verstreken P, Held A, Wainger B, Lyu G, Arenas E, Raulin A, Bu G, Crusius D, Paquet D, Gabriele R, Wray S, Chase K, Zhang K, Marioni J, Skarnes W, Cookson M, Ward M, Merkle F.Cell Stem Cell, 01 Dec 2022, 29(12):1685-1702.e22
DOI: https://doi.org/10.1016/j.stem.2022.11.00410.1016/j.stem.2022.11.004.
Pluripotent stem cells and engineered cells
The consequences of recurrent genetic and epigenetic variants in human pluripotent stem cells.
Andrews PW, Barbaric I, Benvenisty N, Draper JS, Ludwig T, Merkle FT, Sato Y, Spits C, Stacey GN, Wang H, and Pera MF.Cell Stem Cell. 2022 Dec;29(12):1624-1636. DOI: https://doi.org/10.1016/j.stem.2022.11.006
Pluripotent stem cells and engineered cells
Single nucleotide polymorphism (SNP) arrays and their sensitivity for detection of genetic changes in human pluripotent stem cell cultures.
Steventon-Jones, V., Stavish, D., Halliwell, J. A., Baker, D., & Barbaric, I.Current Protocols Volume 2, Issue 11 e606 doi: https://doi.org/10.1002/cpz1.606
Pluripotent stem cells and engineered cells
Selective neurodegeneration generated by intravenous α-synuclein pre-formed fibril administration is not associated with endogenous α-synuclein levels in the rat brain.
Kuan, W-L, Alfaidi, M, Horne, CB, Vallin, B, Fox, S, Fazal, SV, Williams-Gray, CH, Barker, RA.Brain Pathology. 2022. e13128. https://doi.org/10.1111/bpa.13128
Pluripotent stem cells and engineered cells
Substantial somatic genomic variation and selection for BCOR mutations in human induced pluripotent stem cells
Rouhani, FJ., Zou, X., Danecek, P., Badja, C., Dias Amarante, T., Koh, G., Wu, Q., Memari, Y., Durbin, R., Martincorena, I., Bassett, AR., Gaffney, D., Nik-Zainal, S.Nat Genet (2022) 54, 1406-1416. https://doi.org/10.1038/s41588-022-01147-3
Pluripotent stem cells and engineered cells
The need for a standard for informed consent for collection of human fetal material.
Barker, R.A., Boer, G.J., Cattaneo, E., Charo, R.A., Chuva de Sousa Lopes, S.M., Cong, Y., Fujita,M., Goldman, S., Hermerén, G., Hyun, I., Lisgo, S., Rosser, A.E., Anthony, E., & Lindvall, O.Stem Cell Reports, 2022, Volume 17, Issue 6, 14 June 2022, Pages 1245-1247. https://doi.org/10.1016/j.stemcr.2022.05.013.
Parkinson’s disease
, Pluripotent stem cells and engineered cells
Assessing Cell Competition in Human Pluripotent Stem Cell (hPSC) Cultures.
Price CJ, Barbaric I.Curr Protoc. 2022 May;2(5):e435. doi: 10.1002/cpz1.435.
Pluripotent stem cells and engineered cells
A Mathematical Model of a Valve-Controlled Bioreactor for Platelet Production.
Saville, H., Howard, D., Ghevaert, C., Best, S., Cameron, R., Oliver, J., and Waters, S.Frontiers in Mechanical Engineering. 8. 858931. DOI: https://doi.org/10.3389/fmech.2022.858931
Pluripotent stem cells and engineered cells
Amniogenesis occurs in two independent waves in primates.
Rostovskaya M, Andrews S, Reik W, Rugg-Gunn PJ.Cell Stem Cell. 2022 May;29(5):744-759.e6. DOI: https://doi.org/10.1016/j.stem.2022.03.014
Pluripotent stem cells and engineered cells
Assessment of Automated Flow Cytometry Data Analysis Tools within Cell and Gene Therapy Manufacturing.
Cheung M, Campbell JJ, Thomas RJ, Braybrook J, Petzing J.International Journal of Molecular Sciences. 2022; 23(6):3224. https://doi.org/10.3390/ijms23063224
Pluripotent stem cells and engineered cells
Mapping the biogenesis of forward programmed megakaryocytes from induced pluripotent stem cells.
Lawrence, M., Shahsavari, A., Bornelöv, S., Moreau, T., Kania, K., Paramor, M., McDonald, R., Baye, J., Perrin, M., Steindel, M., Jimenez-Gomez, P., Penfold, C., Mohorianu, I., and Ghevaert, C.Sci. Adv. 8 (7), DOI: 10.1126/sciadv.abj8618
Blood – Platelets (Megakaryocytes)
, Pluripotent stem cells and engineered cells
Whole-genome analysis of human embryonic stem cells enables rational line selection based on genetic variation.
Merkle, F.T., Ghosh, S., Genovese, G., Handsaker, R.E., Kashin, S., Meyer, D., Karczewski, K. J., O’Dushlaine, C., Pato, C., Pato, M., MacArthur, D.G., McCarroll, S.A., Eggan, K.Cell Stem Cell 1–15 March 3, 2022. https://doi.org/10.1016/j.stem.2022.01.011
Pluripotent stem cells and engineered cells
CRLF3 plays a key role in the final stage of platelet genesis and is a potential therapeutic target for thrombocythaemia
Bennett, C., Lawrence, M., Guerrero, J.a., Stritt, S., Waller, A.K, Yan, Y., Mifsud, R.W., Ballester-Beltran, J., Baig, A.A., Mueller, A., Mayer, L., Warland, J., Penkett, C.J., Akbari, P., Moreau, T., Evans, A.L., Mookerjee, S., Hoffman,G.J., Saeb-Parsy, K., Adams, D., Couzens, A.L., Bender, M., Erber, W., Nieswandt, B., Read, R.J., Ghevaert, CBlood 2022; blood.2021013113. doi: https://doi.org/10.1182/blood.2021013113
Blood – Platelets (Megakaryocytes)
, Pluripotent stem cells and engineered cells
Systematic design, generation, and application of synthetic datasets for flow cytometry
Cheung, M., Campbell, J.J., Thomas, R.J., Braybrook, J., Petzing, J.PDA Journal of Pharmaceutical Science and Technology Jan 2022, pdajpst.2021.012659; https://doi.org/10.5731/pdajpst.2021.012659
Pluripotent stem cells and engineered cells
Reduced expression of dopamine D2 receptors on astrocytes in R6/1 HD mice and HD post-mortem tissue
Harris, K.L., Mason, S.L., Vallin, B., Barker, R.A.Neuroscience Letters, 767, 10 January 2022, 136289. https://doi.org/10.1016/j.neulet.2021.136289
Parkinson’s disease
, Pluripotent stem cells and engineered cells
2021
Local and systemic responses to SARS-CoV-2 infection in children and adults
Masahiro Yoshida, Kaylee B. Worlock, Ni Huang, Rik G. H. Lindeboom, Colin R. Butler, Natsuhiko Kumasaka, Cecilia Dominguez Conde, Lira Mamanova, Liam Bolt, Laura Richardson, Krzysztof Polanski, Elo Madissoon, Josephine L. Barnes, Jessica Allen-Hyttinen, Eliz Kilich, Brendan C. Jones, Angus de Wilton, Anna Wilbrey-Clark, Waradon Sungnak, J. Patrick Pett, Juliane Weller, Elena Prigmore, Henry Yung, Puja Mehta, Aarash Saleh, Anita Saigal, Vivian Chu, Jonathan M. Cohen, Clare Cane, Aikaterini Iordanidou, Soichi Shibuya, Ann-Kathrin Reuschl, Iván T. Herczeg, A. Christine Argento, Richard G. Wunderink, Sean B. Smith, Taylor A. Poor, Catherine A. Gao, Jane E. Dematte, NU SCRIPT Study Investigators* , Gary Reynolds, Muzlifah Haniffa, Georgina S. Bowyer, Matthew Coates, Menna R. Clatworthy, Fernando J. Calero-Nieto, Berthold Göttgens, Christopher O’Callaghan, Neil J. Sebire, Clare Jolly, Paolo de Coppi, Claire M. Smith, Alexander V. Misharin, Sam M. Janes, Sarah A. Teichmann, Marko Z. Nikolić & Kerstin B. MeyerNature, https://doi.org/10.1038/s41586-021-04345-x (2021)
Engineered cell environment
, Lung
Early development of a polycaprolactone electrospun augment for anterior cruciate ligament reconstruction
L. Savic, E.M. Augustyniak, A. Kastensson, S. Snelling, R.E. Abhari, M. Baldwin, A. Price, W. Jackson, A. Carr, P.A. MouthuyMaterials Science Engineering: C Materials for Biological Applications, 2021, doi: 10.1016/j.msec.2021.112414
Smart Materials
Maintenance of Human Naïve Pluripotent Stem Cells.
Rostovskaya M.In: Rugg-Gunn P. (eds) Human Naïve Pluripotent Stem Cells. Methods in Molecular Biology, vol 2416. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1908-7_6
Pluripotent stem cells and engineered cells
Capacitation of Human Naïve Pluripotent Stem Cells.
Rostovskaya M.In: Rugg-Gunn P. (eds) Human Naïve Pluripotent Stem Cells. Methods in Molecular Biology, vol 2416. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1908-7_9
Pluripotent stem cells and engineered cells
Profiling DNA Methylation in Human Naïve Pluripotent Stem Cells.
von Meyenn F.In: Rugg-Gunn P. (eds) Human Naïve Pluripotent Stem Cells. Methods in Molecular Biology, vol 2416. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1908-7_11
Pluripotent stem cells and engineered cells
Characterizing the genetic stability of human naïve and primed pluripotent stem cells
Baker D., Barbaric I.In: Rugg-Gunn P. (eds) Human Naïve Pluripotent Stem Cells. Methods in Molecular Biology, vol 2416. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1908-7_17
Pluripotent stem cells and engineered cells
Biofunctionalised bacterial cellulose scaffold supports the patterning and expansion of human embryonic stem cell-derived dopaminergic progenitor cells.
Robbins M, Pisupati V, Azzarelli R, Nehme SI, Barker RA, Fruk L, Schierle GSK.Stem Cell Res Ther 12, 574 (2021). https://doi.org/10.1186/s13287-021-02639-5
Parkinson’s disease
, Pluripotent stem cells and engineered cells
The genetic architecture of DNA replication timing in human pluripotent stem cells.
Ding, Q., Edwards, M.M., Wang N., Zhu X., Bracci A.N., Hulke M.L., Hu Y., Tong Y., Hsiao J., Charvet C.J., Ghosh S., Handsaker R.E., Eggan K., Merkle F.T., Gerhardt J., Egli D., Clark A.G., Koren A.Nat Commun 12, 6746 (2021). https://doi.org/10.1038/s41467-021-27115-9
Pluripotent stem cells and engineered cells
Current trends in flow cytometry automated data analysis software.
Cheung, M, Campbell, JJ, Whitby, L, Thomas, RJ, Braybrook, J, Petzing, J.Cytometry. 2021; 99: 1007– 1021. https://doi.org/10.1002/cyto.a.24320
Pluripotent stem cells and engineered cells
Bringing Advanced Therapy Medicinal Products (ATMPs) for Parkinson’s Disease to the Clinic: The Investigator’s Perspective
Barker, R. A., Cutting, E.V., and Daft, D. M.Journal of Parkinson's Disease, vol. 11, no. s2, pp. S129-S134, 2021. DOI: 10.3233/JPD-212563
Parkinson’s disease
, Pluripotent stem cells and engineered cells
The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson’s disease.
Qarin S, Howlett SK, Jones JL, Barker RANeuronal Signal. 2021;5(3):NS20200083. Published 2021 Sep 13.
Parkinson’s disease
, Pluripotent stem cells and engineered cells
Genetically variant human pluripotent stem cells selectively eliminate wild-type counterparts through YAP-mediated cell competition
Price CJ, Stavish D, Gokhale PJ, Stevenson BA, Sargeant S, Lacey J, Rodriguez TA, Barbaric IDevelopmental Cell, Online Aug 2021, https://doi.org/10.1016/j.devcel.2021.07.019.
Pluripotent stem cells and engineered cells
Short-Term Evaluation of Cellular Fate in an Ovine Bone Formation Model.
Markides H, Foster NC, McLaren JS, Hopkins T, Black C, Oreffo ROC, Scammell BE, Echevarria I, White LJ, El Haj AJ.Cells. 2021 Jul 14;10(7):1776. doi: 10.3390/cells10071776.
PMID: 34359945
Engineered cell environment
Tailoring Therapeutic Responses via Engineering Microenvironments with a Novel Synthetic Fluid Gel
Foster NC, Allen P, El Haj AJ, Grover LM, Moakes RJA.Adv Healthc Mater. 2021 Jun 23: e2100622. doi: 10.1002/adhm.202100622.
Engineered cell environment
Translational control of stem cell function.
Saba JA, Liakath-Ali K, Green R, Watt FM.Nat Rev Mol Cell Biol. 2021 Jul 16. doi: 10.1038/s41580-021-00386-2. Online ahead of print.
PMID: 34272502 Review.
Engineered cell environment
Sodium hyaluronate supplemented culture medium combined with joint-simulating mechanical loading improves chondrogenic differentiation of human mesenchymal stem cells
Monaco G, El Haj AJ, Alini M, Stoddart MJ.Eur Cell Mater. 2021 Jun 6;41:616-632. doi: 10.22203/eCM.v041a40.
PMID: 34091884
Engineered cell environment
Process analysis of pluripotent stem cell differentiation to megakaryocytes to make platelets applying European GMP.
Lawrence, M., Evans, A., Moreau, T., Bagnati, M., Smart, M., Hassan, E., Hasan, J., Pianella, M., Kerby, J., Ghevaert, C.npj Regen Med 6, 27 (2021). https://doi.org/10.1038/s41536-021-00138-y
Blood – Platelets (Megakaryocytes)
, Pluripotent stem cells and engineered cells
Nanopore sequencing indicates that tandem amplification of chromosome 20q11.21 in human pluripotent stem cells is driven by break induced replication.
Halliwell J, Baker D, Judge K, Quail MA, Oliver K, Betteridge E, Skelton J, Andrews PW, Barbaric I.Stem Cells and Development.Jun 2021.578-586. https://doi.org/10.1089/scd.2021.0013
Cell behaviour, differentiation and manufacturing (UKRMP1)
, Pluripotent stem cells and engineered cells
Two-Dimensional and Three-Dimensional Cartilage Model Platforms for Drug Evaluation and High-Throughput Screening Assays
Foster NC, Hall NM, El Haj AJ.Tissue Eng Part B Rev. 2021 May 19. doi: 10.1089/ten.teb.2020.0354.
Engineered cell environment
, Musculoskeletal
Linking chondrocyte and synovial transcriptional profile to clinical phenotype in osteoarthritis
Steinberg J, Southam L, Fontalis A, Clark MJ, Jayasuriya RL, Swift D, Shah KM, Brooks RA, McCaskie AW, Wilkinson JM, Zeggini E.Ann Rheum Dis. 2021 Apr 26:annrheumdis-2020-219760. doi: 10.1136/annrheumdis-2020-219760. Online ahead of print.
PMID: 33903094
Engineered cell environment
A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage.
Zou, X., Koh, G.C.C., Nanda, A.S., Degasperi, A., Urgo, K., Roumeliotis, T.I., Agu, C.A., Badja, C., Momen, S., Young, J., Amarante, T.D., Side, L., Brice, G., Perez-Alonso, V., Rueda, D., Gomez, C., Bushell, W., Harris, R., Choudhary, J.S., Genomics England Research Consortium, Jiricny, J., Skarnes, W.C. & Nik-Zainal, S.Nat Cancer (2021). https://doi.org/10.1038/s43018-021-00200-0
Pluripotent stem cells and engineered cells
Fitness selection in human pluripotent stem cells and interspecies chimeras: Implications for human development and regenerative medicine
Wu, J. and Barbaric, I.Developmental Biology (2021) Volume 476; 209-217. https://doi.org/10.1016/j.ydbio.2021.03.025.
Pluripotent stem cells and engineered cells
Single-cell multi-omics analysis of the immune response in COVID-19
Stephenson E, Reynolds G, Botting RA, Calero-Nieto FJ, Morgan MD, Tuong ZK, Bach K, Sungnak W, Worlock KB, Yoshida M, Kumasaka N, Kania K, Engelbert J, Olabi B, Spegarova JS, Wilson NK, Mende N, Jardine L, Gardner LCS, Goh I, Horsfall D, McGrath J, Webb S, Mather MW, Lindeboom RGH, Dann E, Huang N, Polanski K, Prigmore E, Gothe F, Scott J, Payne RP, Baker KF, Hanrath AT, Schim van der Loeff ICD, Barr AS, Sanchez-Gonzalez A, Bergamaschi L, Mescia F, Barnes JL, Kilich E, de Wilton A, Saigal A, Saleh A, Janes SM, Smith CM, Gopee N, Wilson C, Coupland P, Coxhead JM, Kiselev VY, van Dongen S, Bacardit J, King HW; Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID-19 BioResource Collaboration, Rostron AJ, Simpson AJ, Hambleton S, Laurenti E, Lyons PA, Meyer KB, Nikolić MZ, Duncan CJA, Smith KGC, Teichmann SA, Clatworthy MR, Marioni JC, Göttgens B, Haniffa M.Nat Med. 2021 Apr 20. doi: 10.1038/s41591-021-01329-2. Online ahead of print.PMID: 33879890
Engineered cell environment
Regenerative medicine meets mathematical modelling: developing symbiotic relationships
Waters S L , Schumacher L J, El Haj APMID: 33846347, PMCID: PMC8042047, DOI: 10.1038/s41536-021-00134-2 Free PMC article
Engineered cell environment
Widespread reorganisation of pluripotent factor binding and gene regulatory interactions between human pluripotent states.
Chovanec, P., Collier, AJ., Krueger, C., Várnai, C., Semprich, CI., Schoenfelder, S., Corcoran, AE., Rugg-Gunn, PJ.Nat Commun 12, 2098 (2021). https://doi.org/10.1038/s41467-021-22201-4
Pluripotent stem cells and engineered cells
Understanding cell culture dynamics: a tool for defining protocol parameters for improved processes and efficient manufacturing using human embryonic stem cells.
Kusena, J.W.T., Shariatzadeh, M., Thomas, R.J., & Wilson, S.J.Bioengineered, 12:1, 979-996, DOI: 10.1080/21655979.2021.1902696
Pluripotent stem cells and engineered cells
Defining the signalling determinants of a posterior ventral spinal cord identity in human neuromesodermal progenitor derivatives.
Wind, M., Gogolou, A., Manipur, I., Granata, I., Butler, L., Andrews, PW., Barbaric, I., Ning, K., Guarracino, MR., Placzek, M., Tsakiridis, A.Development 2021 148: doi: 10.1242/dev.194415
Pluripotent stem cells and engineered cells
Population-scale single-cell RNA-seq profiling across dopaminergic neuron differentiation.
Jerber, J., Seaton, D.D., Cuomo, A.S.E., Kumasaka, N., Haldane, J., Steer, J., Patel, M., Pearce, D., Andersson, M., Jan Bonder, M., Mountjoy, E., Ghoussaini, M., Lancaster, M.A., HipSci Consortium, Marioni, J.C., Merkle, F.T., Gaffney, D.J., Stegle, O.Nat Genet 53, 304–312 (2021). https://doi.org/10.1038/s41588-021-00801-6
Parkinson’s disease
, Pluripotent stem cells and engineered cells
Chapter 3 – Advances in stem cell biology: induced pluripotent stem cells—novel concepts iPSC-derived megakaryocytes,
Lawrence M., & Ghevaert C.Editor(s): Alexander Birbrair,
In Advances in Stem Cell Biology,
Recent Advances in iPSC-Derived Cell Types,
Academic Press,
Volume 4,
2021,
Pages 49-67,
ISBN 9780128222300,
Blood – Platelets (Megakaryocytes)
, Pluripotent stem cells and engineered cells
High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need
Hughes R E, Elliot R J R, Dawson J C, Carragher N O.PMID: 33740435 DOI: 10.1016/j.chembiol.2021.02.015
Engineered cell environment
The importance of cell culture parameter standardization: an assessment of the robustness of the 2102Ep reference cell line.
Kusena, J.W.T, Shariatzadeh, M., Studd, A.J., James, J.R., Thomas, R.J., & Wilson, S.L.Bioengineered (2021), 12:1, 341-357, DOI: 10.1080/21655979.2020.1870074
Pluripotent stem cells and engineered cells
2020
A blueprint for translational regenerative medicine,
Armstrong JPK, Keane TJ, Roques AC, Stephen Patrick P, Mooney CM, Kuan W-L, Pisupati V, Oreffo ROC, Stuckey D, Watt FM, Forbes SJ, Barker RA, Stevens M.Science Translational Medicine 02 Dec 2020, Vol. 12, Issue 572,
DOI: 10.1126/scitranslmed.aaz2253
Engineered cell environment
, Pluripotent stem cells and engineered cells
, Smart Materials
Transcription-dependent cohesin repositioning rewires chromatin loops in cellular senescence.
Olan I, Parry AJ, Schoenfelder S, Narita M, Ito Y, Chan ASL, Slater G, Bihary D, Bando M, Shirahige K, Kimura H, Samarajiwa SA, Fraser P, Narita M.Nat Commun 11, 6049 (2020).
https://doi.org/10.1038/s41467-020-19878-4
Pluripotent stem cells and engineered cells
, Year
Gene and Cell-Based Therapies for Parkinson’s Disease: Where Are We?
Buttery, P.C., Barker, R.A.Neurotherapeutics (2020) 17, 1539–1562. https://doi.org/10.1007/s13311-020-00940-4
Parkinson’s disease
, Pluripotent stem cells and engineered cells
Animal Models of Parkinson’s Disease: Are They Useful or Not?
Barker, R. A. and Björklund, A.Journal of Parkinson's Disease (2020), 10 (4) pp. 1335-1342, 2020. https://doi.org/10.3233/jpd-202200
Parkinson’s disease
, Pluripotent stem cells and engineered cells
Generation and trapping of a mesoderm biased state of human pluripotency.
Stavish, D., Böiers, C., Price, C., Frith TJ., Halliwell J., Saldana-Guerrero I., Wray J., Brown J., Carr J., James C., Barbaric I, Andrews PW., Enver TNat Commun 11, 4989 (2020).
https://doi.org/10.1038/s41467-020-18727-8
Cell behaviour, differentiation and manufacturing (UKRMP1)
, Pluripotent stem cells and engineered cells
Epithelial Plasticity during Liver Injury and Regeneration
Gadd V L, Aleksieva N, Forbes S JCell Stem Cell 2020 Oct 1;27(4):557-573.
doi: 10.1016/j.stem.2020.08.016.
Engineered cell environment
, Liver
Acquired genetic changes in human pluripotent stem cells: origins and consequences.
Halliwell, J., Barbaric, I., Andrews, P.WNat Rev Mol Cell Biol (2020).
https://doi.org/10.1038/s41580-020-00292-z
Pluripotent stem cells and engineered cells
Cell Therapy for Advanced Liver Diseases: Repair or Rebuild
Dwyer B J, Macmillan M T, Brennan P N, Forbes S JJ Hepatol. 2020 Sep 22;S0168-8278(20)33626-6.
doi: 10.1016/j.jhep.2020.09.014.
Engineered cell environment
, Liver
Wnt-modified materials mediate asymmetric stem cell division to direct human osteogenic tissue formation for bone repair
Okuchi Y, Reeves J, Ng S S, Doro D H, Junyent S, Liu K J, El Haj A J & Habib S JNat Mater. 2020 Sep 21.
doi: 10.1038/s41563-020-0786-5.
Engineered cell environment
, Musculoskeletal
GMP-grade neural progenitor derivation and differentiation from clinical-grade human embryonic stem cells.
Vitillo, L., Durance, C., Hewitt, Z., Moore, H.D., Smith, A., Vallier, L.Stem Cell Res Ther 11, 406 (2020).
https://doi.org/10.1186/s13287-020-01915-0
Cell behaviour, differentiation and manufacturing (UKRMP1)
, Pluripotent stem cells and engineered cells
Retinoic Acid Accelerates the Specification of Enteric Neural Progenitors from In-Vitro-Derived Neural Crest.
Firth, T.J.R, Gogolou, A., Hackland, J.O.S., Hewitt, Z.A., Moore, H.D., Barbaric, I., Thapar, N., Burns, A.J., Andrews, P.W., Tsakiridis, A., McCann, C.J.Stem Cell Reports, 15(3) 8 Sep 2020.
https://doi.org/10.1016/j.stemcr.2020.07.024
Pluripotent stem cells and engineered cells
DNA Fiber Assay for the Analysis of DNA Replication Progression in Human Pluripotent Stem Cells.
Halliwell JA, Gravells P, Bryant HE.Current Protocols in Stem Cell Biology. 2020 Sep;54(1):e115. https://doi.org/10.1002/cpsc.115
Pluripotent stem cells and engineered cells
Cohesin-dependent and independent mechanisms support chromosomal contacts between promoters and enhancers.
Thiecke MJ, Wutz G, Muhar M, Tang W, Bevan S, Malysheva V, Stocsits R, Neumann T, Zuber J, Fraser P, Schoenfelder S, Peters JM, Spivakov M.Cell Reports July 2020, 32, 107929,
doi: https://doi.org/10.1016/j.celrep.2020.107929
Pluripotent stem cells and engineered cells
Bioengineered airway epithelial grafts with mucociliary function based on collagen IV- and laminin-containing extracellular matrix scaffolds
Hamilton N J I, Lee D D H, Gowers K H C, Butler C R, Maughan E F, Jevans B, Orr J C, McCann C J, Burns A J, MacNeil S, Birchall M A, O'Callaghan C, Hynds R E and Janes S M.European Respiratory Journal
DOI: 10.1183/13993003.01200-2019
Engineered cell environment
, Lung
SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues,
Ziegler C G K, Allon S J, Nyquist S K ... Shalek A K, Ordovas-Montanes J, HCA Lung Biological NetworkCell (2020)
doi: https://doi.org/10.1016/j.cell.2020.04.035.
Engineered cell environment
, Lung
Controlling Electrospun Polymer Morphology for Tissue Engineering Demonstrated Using hepG2 Cell Line
Bate T S R, Forbes S J, Callanan A.J Vis Exp.(159).
doi: 10.3791/61043.
Engineered cell environment
, Liver
High-Content Phenotypic Profiling in Esophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug Discovery
Hughes R E, Elliott R J R, Munro A F, Makda A, O'Neill J R, Hupp T, Carragher N O.SLAS Discov. 2020 Aug;25(7):770-782.
doi: 10.1177/2472555220917115.
Engineered cell environment
Three-Dimensional Surface-Based Analysis of Cartilage MRI Data in Knee Osteoarthritis: Validation and Initial Clinical Application
MacKay JW, Kaggie JD, Treece GM, McDonnell SM, Khan W, Roberts AR, Janiczek RL, Graves MJ, Turmezei TD, McCaskie AW, Gilbert FJ.J Magn Reson Imaging. 2020 Oct;52(4):1139-1151. doi: 10.1002/jmri.27193. Epub 2020 May 24.
Engineered cell environment
Changes in the Oligodendrocyte Progenitor Cell Proteome with Ageing
de la Fuente A G, Queiroz R M L, Ghosh T, McMurran C E, Cubillos J F, Bergles D E, . . . Franklin R J M.Molecular & Cellular Proteomics, 19(8), 1281-1302.
doi:10.1074/mcp.ra120.002102
Engineered cell environment
, Multiple sclerosis
TFEB regulates murine liver cell fate during development and regeneration
Pastore N, Huynh T, Herz N J, Calcagni A, Klisch T J, Brunetti L, Kim K H, De Giorgi M, Hurley A, Carissimo A, Mutarelli M, Aleksieva N, D'Orsi L, Lagor W R, Moore D D, Settembre C, Finegold M J, Forbes S J, Ballabio A.Nat Commun. 11(1):2461.
doi: 10.1038/s41467-020-16300-x.
Engineered cell environment
, Liver
Nucleosides rescue replication-mediated genome instability of human pluripotent stem cells
Halliwell JA, Frith TJR, Laing O, Price CJ, Bower OJ, Stavish D, Gokhale PJ, Hewitt Z, El-Khamisy SF, Barbaric I, Andrews PWStem Cell Reports. 2020 June 9, 14: 1009–1017.
https://doi.org/10.1016/j.stemcr.2020.04.004
Pluripotent stem cells and engineered cells
Hepatic Progenitor Specification from Pluripotent Stem Cells Using a Defined Differentiation System
Meseguer-Ripolles J, Wang Y, Sorteberg A, Sharma A, Ding N, Lucendo-Villarin B, Kramer P, Segeritz C, Hay DJ. Vis. Exp. (159), e61256
doi:10.3791/61256 (2020)
Engineered cell environment
, Engineering and exploiting the stem cell niche (UKRMP1)
, Liver
Assessing Human Embryonic Stem Cell-Derived Dopaminergic Neuron Progenitor Transplants Using Non-invasive Imaging Techniques
Mousavinejad M. , Skidmore S., Barone F. G., Tyers P., Pisupati V., Poptani H., Plagge A., Barker R. A., Murray P., Taylor A., Hill C. J.Mol Imaging Biol 22, 1244–1254 (2020).
doi: 10.1007/s11307-020-01499-4
Parkinson’s disease
, Pluripotent stem cells and engineered cells
Mouth-Watering Results: Clinical Need, Current Approaches, and Future Directions for Salivary Gland Regeneration.
Rocchi C, Emmerson E.Trends Mol Med. 2020 Jul;26(7):649-669.
doi.org/10.1016/j.molmed.2020.03.009
Engineered cell environment
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes
Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, Talavera-López C, Maatz H, Reichart D, Sampaziotis F, Worlock K, Yoshida M, Barnes J & HCA Lung Biological NetworkNat Med 26, 681–687 (2020).
https://doi.org/10.1038/s41591-020-0868-6
Engineered cell environment
, Lung
A Fluorescent Molecular Imaging Probe with Selectivity for Soluble Tau Aggregated Protein
Zhao YY, Tietz O, Kuan WL, Haji-Dheere AK, Thompson S, Vallin B, Ronchi E, Tóth G, Klenerman D, Aigbirhio FIChemical Science, 2020, 11, 4773-4778.
doi: 10.1039/c9sc05620c
Parkinson’s disease
, Pluripotent stem cells and engineered cells
Cell-intrinsic differences between human airway epithelial cells from children and adults
Maughan E F, Nigro E, Pennycuick A, Gowers K H C, Denais C, Gómez-López S, Lazarus K A, Butler C R, Lee D D H, Orr J C, Teixeira V H, Hartley B E, Hewitt R J, Al Yaghchi C, Sandhu G S, Birchall M A, O'Callaghan C, Smith C M, De Coppi P, Hynds R E, Janes S M.doi: https://doi.org/10.1101/2020.04.20.027144
Engineered cell environment
, Lung
Phenotype instability of hepatocyte-like cells produced by direct reprogramming of mesenchymal stromal cells
Orge I, Gadd V, Barouh V, Rossi E, Carvalho R, Smith I, Allahdadi K, Paredes B, Silva D, Damasceno P, Sampaio G, Forbes S, Soares M & Souza B.Stem Cell Research & Therapy (2020) 11:154
https://doi.org/10.1186/s13287-020-01665-z
Engineered cell environment
, Liver
Absolute measurement of the tissue origins of cell-free DNA in the healthy state and following paracetamol overdose
Laurent D, Semple F, Starkey Lewis P J, Rose E, Black H A, Coe J, Forbes S J, Arends M J, Dear J W, Aitman T J.BMC Med Genomics; 13(1):60.
doi: 10.1186/s12920-020-0705-2.
Engineered cell environment
, Engineering and exploiting the stem cell niche (UKRMP1)
, Liver
Regional differences in human biliary tissues and corresponding in vitro derived organoids
Rimland C A, Tilson S G, Morell C M, Tomaz R A, Lu W Y, Adams S E, Georgakopoulos N, Otaizo-Carrasquero F, Myers T G, Ferdinand J R, Gieseck R L, Sampaziotis F, Tysoe O C, Wesley B, Muraro D, Oniscu G C, Hannan N F, Forbes S J, Saeb-Parsy K, Wynn T A, Vallier L.Hepatology
doi: 10.1002/hep.31252.
Engineered cell environment
, Engineering and exploiting the stem cell niche (UKRMP1)
, Liver
Low rates of mutation in clinical grade human pluripotent stem cells under different culture conditions
Thompson O., von Meyenn F., HewittZ., Alexander J., Wood A., Weightman R., Gregory S., Krueger F., Andrews S., Barbaric I., Gokhale P.J., Moore H.D., Reik W., Milo M., Nik-Zainal S., Yusa K. & Andrews P.W.Low rates of mutation in clinical grade human pluripotent stem cells under different culture conditions.
Nat Commun 11, 1528 (2020).
https://doi.org/10.1038/s41467-020-15271-3
Cell behaviour, differentiation and manufacturing (UKRMP1)
, Pluripotent stem cells and engineered cells
Specialized cytonemes induce self-organization of stem cells
Junyent S, Garcin C L, Szczerkowski J L A, Trieu T J, Reeves J, Habib S JProc Natl Acad Sci U S A. 2020 Mar 31;117(13):7236-7244
doi: 10.1073/pnas.1920837117
Engineered cell environment
, Engineering and exploiting the stem cell niche (UKRMP1)
, Musculoskeletal
Alternatively activated macrophages promote resolution of necrosis following acute liver injury
Starkey Lewis P, Campana L, Aleksieva N, Cartwright J A, Mackinnon A, O'Duibhir E, Kendall T, Vermeren M, Thomson A, Gadd V, Dwyer B, Aird R, Man TY, Rossi A G, Forrester L, Park B K, Forbes S J.J Hepatol. 73(2):349-360
doi: 10.1016/j.jhep.2020.02.031
Engineered cell environment
, Engineering and exploiting the stem cell niche (UKRMP1)
, Liver
Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson’s disease
Wijeyekoon RS, Kronenberg-Versteeg D, Scott KM, Hayat S, Kuan WL, Evans JR, Breen DP, Cummins G, Jones JL, Clatworthy MR, Floto RA, Barker RA, Williams-Gray CH.Brain Behavior and Immunity. 2020; 87:473-488.
doi:10.1016/j.bbi.2020.01.018
Parkinson’s disease
, Pluripotent stem cells and engineered cells
2019
Distributed automated manufacturing of pluripotent stem cell products.
Shariatzadeh M, Chandra A, Wilson SL, McCall MJ, Morizur L, Lesueur L, Chose O, Gepp MM, Schulz A, Neubauer JC, Zimmermann H, Abranches E, Man J, O’Shea O, Stacey G, Hewitt Z, Williams DInt J Adv Manuf Technol 106, 1085–1103 (2020)
doi:10.1007/s00170-019-04516-1
Cell behaviour, differentiation and manufacturing (UKRMP1)
, Pluripotent stem cells and engineered cells
Regenerative Medicine: “Are We There Yet?”
El Haj AJTissue Eng Part A. 2019;25(15-16):1067–1071.
doi:10.1089/ten.TEA.2019.0134
Engineered cell environment
, Musculoskeletal
Systemic α-synuclein injection triggers selective neuronal pathology as seen in patients with Parkinson’s disease.
Kuan WL, Stott K, He X, Wood TC, Yang S, Kwok JCF, Hall K, Zhao Y, Tietz O, Aigbirhio FI, Vernon AC, Barker RAMol Psychiatry 2019 Nov 22.
doi:10.1038/s41380-019-0608-9.
Parkinson’s disease
, Pluripotent stem cells and engineered cells
Serum Raman spectroscopy as a diagnostic tool in patients with Huntington’s disease
Kuan WL*, Huefner A*, Mason SL, Mahajan S, Barker RA.Chemical Science, 2020,11, 525-533
doi: 10.1039/c9sc03711j.
Pluripotent stem cells and engineered cells
From protocol to product: ventral midbrain dopaminergic neuron differentiation for the treatment of Parkinson’s disease.
Kusena JWT., Thomas RT., McCall MJ., Wilson SLRegen Med 2019 14:11 https://doi.org/10.2217/rme-2019-0076
Parkinson’s disease
, Pluripotent stem cells and engineered cells
Remyelination and Ageing: Reversing the Ravages of Time
Neumann B, Segel M, Chalut KJ, Franklin RJMult Scler. 2019;25(14):1835–1841.
doi:10.1177/1352458519884006
Engineered cell environment
Safety Profile of Autologous Macrophage Therapy for Liver Cirrhosis
Moroni F, Dwyer BJ, Graham C, Pass C, Bailey L, Ritchie L, Mitchell D, Glover A, Laurie A, Doig S, Hargreaves E, Fraser AR, Turner ML, Campbell JDM, McGowan NWA, Barry J, Moore JK, Hayes PC, Leeming DJ, Nielsen MJ, Musa K, Fallowfield JA, Forbes SJNat Med 25, 1560–1565 (2019)
doi:10.1038/s41591-019-0599-8
Engineered cell environment
, Engineering and exploiting the stem cell niche (UKRMP1)
, Liver
Niche Stiffness Underlies the Ageing of Central Nervous System Progenitor Cells
Segel M, Neumann B, Hill MFE, Weber IP, Viscomi C, Zhao C, Young A, Agley CC, Thompson AJ, Gonzalez GA, Sharma A, Holmqvist S, Rowitch DH, Franze K, Franklin RJM, Chalut KJ[published correction appears in Nature. 2019 Aug 29;:].
Nature. 2019;573(7772):130–134.
doi:10.1038/s41586-019-1484-9
Engineered cell environment
A Professional Standard for Informed Consent for Stem Cell Therapies.
Sugarman J, Barker RA, Charo RA.JAMA. 2019;322(17):1651–1652. doi:10.1001/jama.2019.11290
Pluripotent stem cells and engineered cells
Serum Free Production of Three-dimensional Human Hepatospheres from Pluripotent Stem Cells
Lucendo-Villarin B, Rashidi H, Alhaque S, Fischer L, Meseguer-Ripolles J, Wang Y, O'Farrelly C, Themis M, Hay DCJ Vis Exp. 2019;(149):10.3791/59965.
Published 2019 Jul 20.
doi:10.3791/59965
Engineered cell environment
, Liver
Designing stem-cell-based dopamine cell replacement trials for Parkinson’s disease.
Barker, R.A., TRANSEURO consortium.Nat Med (2019) 25, 1045–1053 (2019). https://doi.org/10.1038/s41591-019-0507-2
Parkinson’s disease
, Pluripotent stem cells and engineered cells
Using genome editing to engineer universal platelets
Lawrence M, Mueller A, Ghevaert CEmerg Top Life Sci (2019) 3 (3): 301–311.
doi:10.1042/etls20180153
Blood – Platelets (Megakaryocytes)
, Pluripotent stem cells and engineered cells
Stem cell culture conditions and stability: a joint workshop of the PluriMes Consortium and Pluripotent Stem Cell Platform.
Stacey GN, Andrews PW, Barbaric I, Boiers C, Chandra A, Cossu G, Csontos L, Frith TJ, Halliwell JA, Hewitt Z, McCall M, Moore HD, Parmar M, Panico MB, Pisupati V, Shichkin VP, Stacey AR, Tedesco FS, Thompson O, Wagey RRegen Med. 2019 Mar;14(3):243-255.
doi: 10.2217/rme-2019-0001. Epub 2019 Apr 2.
Cell behaviour, differentiation and manufacturing (UKRMP1)
, Pluripotent stem cells and engineered cells
Anti-apoptotic Mutations Desensitize Human Pluripotent Stem Cells to Mitotic Stress and Enable Aneuploid Cell Survival
Zhang J, Hirst AJ, Duan F, Qiu H, Huang R, Ji Y, Bai L, Zhang F, Robinson D, Jones M, Li L, Wang P, Jiang P, Andrews PW, Barbaric I, Na JStem Cell Reports. 2019 Mar 5;12(3):557-571.
doi:10.1016/j.stemcr.2019.01.013.
Cell behaviour, differentiation and manufacturing (UKRMP1)
, Pluripotent stem cells and engineered cells
Rapid PCR Assay for Detecting Common Genetic Variants Arising in Human Pluripotent Stem Cell Cultures.
Laing O, Halliwell J, Barbaric ICurr Protoc Stem Cell Biol. 2019 Jun;49(1):e83.
doi:10.1002/cpsc.83. Epub 2019 Mar 1.
Pluripotent stem cells and engineered cells
Capacitation of human naïve pluripotent stem cells for multi-lineage differentiation
Rostovskaya M., Stirparo, G.G., & Smith ADevelopment (2019) 146 (7):dev.172916
Cell behaviour, differentiation and manufacturing (UKRMP1)
, Pluripotent stem cells and engineered cells
Transcriptional Heterogeneity in Naïve and Primed Human Pluripotent Stem Cells at Single-Cell Resolution
von Meyenn F, Messmer T, Savino A, Santos F, Mohammed H, Tin Long Lun A, Marioni JC, Reik WCell Rep. 2019 Jan 22;26(4):815-824.e4.
doi:10.1016/j.celrep.2018.12.099.
Pluripotent stem cells and engineered cells
2018
Science-based assessment of source materials for cell-based medicines: report of a stakeholders workshop.
Stacey G, Andrews P, Asante C, Barbaric I, Barry J, Bisset L, Braybrook J, Buckle R, Chandra A, Coffey P, Crouch S, Driver P, Evans A, Gardner J, Ginty P, Goldring C, Hay DC, Healy L, Hows A, Hutchinson C, Jesson H, Kalber T, Kimber S, Leathers R, Moyle S, Murray T, Neale M, Pan D, Park BK, Rebolledo RE, Rees I, Rivolta MN, Ritchie A, Roos EJ, Saeb-Parsy K, Schröder B, Sebastian S, Thomas A, Thomas RJ, Turner M, Vallier L, Vitillo L, Webster A, Williams D.Regen Med. 2018 Dec;13(8):935-944.
doi: 10.2217/rme-2018-0120. Epub 2018 Nov 29.
Cell behaviour, differentiation and manufacturing (UKRMP1)
, Pluripotent stem cells and engineered cells
Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report
Sugarman, J., Barker, RA., Kerridge, I., Lysaght T., Pellegrini, G., Sipp, D., & Tanner, C.Stem Cell Reports (2018), 11 (5), 1021-1025. https://doi.org/10.1016/j.stemcr.2018.10.020
Pluripotent stem cells and engineered cells
Glycosylated superparamagnetic nanoparticle gradients for osteochondral tissue engineering
Li C, Armstrong JPK, Pence IJ, Kit-Anan W, Puetzer JL, Carreira SC, Moore AC, Stevens MMBiomaterials. 2018 Sep; 176: 24–33. doi: 10.1016/j.biomaterials.2018.05.029. PMID: 29852377
Acellular (UKRMP1)
, Musculoskeletal
3D human liver tissue from pluripotent stem cells displays stable phenotype in vitro and supports compromised liver function in vivo
Rashidi H, Luu NT, Alwahsh SM, Ginai M, Alhaque S, Dong H, Tomaz RA, Vernay B, Vigneswara V, Hallett JM, Chandrashekran A, Dhawan A, Vallier L, Bradley M, Callanan A, Forbes SJ, Newsome PN, Hay DC.Arch Toxicol (2018).
DOI: https://doi.org/10.1007/s00204-018-2280-2
Engineered cell environment
, Engineering and exploiting the stem cell niche (UKRMP1)
, Liver
Human lung development: recent progress and new challenges
Nikolic, MZ, Sun D, Rawlins ELDevelopment 2018 145: dev163485
doi: 10.1242/dev.163485
Published 15 August 2018
Engineered cell environment
, Lung
Regenerative Therapies for Parkinson’s Disease: An Update
Stoker, T., & Barker, R.BioDrugs (2018), 32 (4), 357-366.
https://doi.org/10.1007/s40259-018-0294-1
Parkinson’s disease
, Pluripotent stem cells and engineered cells
Multimodal cell tracking from systemic administration to tumour growth by combining gold nanorods and reporter genes
Comenge J, Sharkey J, Fragueiro O, Wilm B, Mathias Brust M, Murray P, Levy R, Plagge A.Accepted eLife Jun 2018
doi: https://doi.org/10.1101/199836
Safety and efficacy, focusing on imaging technologies (UKRMP1)
Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury.
Goldring C, Antoine DJ, Bonner F, Crozier J, Denning C, Fontana RJ, Hanley NA, Hay DC, Ingelman-Sundberg M, Juhila S, Kitteringham N, Silva-Lima B, Norris A, Pridgeon C, Ross JA, Young RS, Tagle D, Tornesi B, van de Water B, Weaver RJ, Zhang F, Park BK.Hepatology. 2017 Feb; 65(2): 710-721.
doi: 10.1002/hep.28886.
Epub 2016 Nov 30.
Engineering and exploiting the stem cell niche (UKRMP1)
, Liver
Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis
Medina-Rodríguez EM, Bribián A,, Boyd A, Palomo V, Pastor J, Lagares A, Gil C, Martínez A, Williams A, de Castro F,.Sci Rep. 2017 Mar 3;7:43545.
doi: 10.1038/srep43545.
Engineering and exploiting the stem cell niche (UKRMP1)
, Multiple sclerosis
The STAT3–IL-10–IL-6 Pathway Is a Novel Regulator of Macrophage Efferocytosis and Phenotypic Conversion in Sterile Liver Injury.
Lara Campana, Philip J. Starkey Lewis, Antonella Pellicoro, Rebecca L. Aucott, Janet Man, Eoghan O’Duibhir, Sarah E. Mok, Sofia Ferreira-Gonzalez, Eilidh Livingstone, Stephen N. Greenhalgh, Katherine L. Hull, Timothy J. Kendall, Douglas Vernimmen, Neil C. Henderson, Luke Boulter, Christopher D. Gregory, Yi Feng, Stephen M. Anderton, Stuart J. Forbes and John P. IredaleJ. Immunol. 2017.
doi:10.4049/jimmunol.1701247.
Epub 2017 Dec 20.
Engineering and exploiting the stem cell niche (UKRMP1)
, Liver
Extracellular Matrix Molecule-Based Capture of Mesenchymal Stromal Cells Under Flow
Massam-Wu T, Cain SA, Kielty CM.Methods Mol Biol. 2018; 1722: 249-560.
doi:10.1007/978-1-4939-7553-2_16.
Engineering and exploiting the stem cell niche (UKRMP1)
Auxetic Cardiac Patches with Tunable Mechanical and Conductive Properties toward Treating Myocardial Infarction
Kapnisi M, Mansfield C, Marijon C, Guex AG, Perbellini F, Bardi I, Humphrey EJ, Puetzer JL, Mawad D, Koutsogeorgis DC, Stuckey DJ, Terracciano CM, Harding SE, Stevens MMAdv Funct Mater. 2018 May 24; 28(21): doi: 10.1002/adfm.201800618
PMCID: PMC5985945
Acellular (UKRMP1)
, Cardiovascular
The Challenges of First-in-Human Stem Cell Clinical Trials: What Does This Mean for Ethics and Institutional Review Boards?
Barker, R., Carpenter, M. K., Forbes, S., Goldman, S. A., Jamieson, C., Murry, C. E., Takahashi, J., & Weir G.,Stem cell reports (2018) 10 (5), 1429-1431.
https://doi.org/10.1016/j.stemcr.2018.04.010
Parkinson’s disease
, Pluripotent stem cells and engineered cells
Immunomodulatory role of keratin 76 in oral and gastric cancer.
Sequeira I, Carrero D, Peng Q, Palasz N, Liakath-Ali K, Lord G, Morgan P, Lombardi G, Watt FM.BioRxiv https://doiorg/101101/305961. 2018.
Immunomodulation (UKRMP1)
Experimentally integrated dynamic modelling for intuitive optimisation of cell based processes and manufacture
Stacey, A.J., Cheeseman, E.A., Glen, K.E., Moore R.L.L., Thomas, R.J.Biochemical Engineering Journal (2018), 132, 130-138. https://doi.org/10.1016/j.bej.2018.01.012
Cell behaviour, differentiation and manufacturing (UKRMP1)
, Pluripotent stem cells and engineered cells
Spatial and Single-Cell Transcriptional Profiling Identifies Functionally Distinct Human Dermal Fibroblast Subpopulations.
Philippeos C, Telerman SB, Oulès B, Pisco AO, Shaw TJ, Elgueta R, Lombardi G, Driskell RR, Soldin M, Lynch MD, Watt FM.J Invest Dermatol. 2018;138(4):811-25.
PMCID: PMC5869055
DOI: 10.1016/j.jid.2018.01.016
Immunomodulation (UKRMP1)
Harnessing Nanotopography to Enhance Osseointegration of Clinical Orthopedic Titanium Implants—An in Vitro and in Vivo Analysis
Goriainov V, Hulsart-Billstrom G, Sjostrom T, Dunlop DG, Su B, Oreffo ROCFront Bioeng Biotechnol. April 11 2018; 6: 44. doi: 10.3389/fbioe.2018.00044 PMCID: PMC5905351
Acellular (UKRMP1)
, Musculoskeletal
Developing defined substrates for stem cell culture and differentiation
Hagbard L, Cameron K, August P, Penton C, Parmar M, Hay DC, Kallur TPhil. Trans. R. Soc. B 373: 20170230.
http://dx.doi.org/10.1098/rstb.2017.0230
Engineering and exploiting the stem cell niche (UKRMP1)
Paracrine cellular senescence exacerbates biliary injury and impairs regeneration
Ferreira-Gonzalez S, Lu WY, Raven A, Dwyer B, Man TY, O'Duibhir E, Lewis PJS, Campana L, Kendall TJ, Bird TG,,, Tarrats N, Acosta JC, Boulter L, Forbes SJ.Nat Commun. 2018 Mar 9;9(1):1020.
doi: 10.1038/s41467-018-03299-5.
Engineering and exploiting the stem cell niche (UKRMP1)
Imaging-Based Screen Identifies Laminin 411 as a Physiologically Relevant Niche Factor with Importance for i-Hep Applications
Ong J, Serra MP, Segal J, Cujba AM, Ng SS, Butler R, Millar V, Hatch S, Zimri S, Koike H, Chan K, Bonham A, Walk M, Voss T, Heaton N, Mitry R, Dhawan A, Ebner D, Danovi D, Nakauchi H, Rashid ST.Stem Cell Reports. 2018 Mar 13;10(3):693-702.
doi: 10.1016/j.stemcr.2018.01.025.
Epub 2018 Mar 1.
Engineering and exploiting the stem cell niche (UKRMP1)
, Liver
Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy.
Fuhrmann G, Chandrawati R, Parmar PA, Keane TJ, Maynard SA, Bertazzo S, Stevens MM.Adv Mater. 2018 Feb 23. doi: 10.1002/adma.201706616. PMID: 2947323
Acellular (UKRMP1)
Liposomal Delivery of Demineralized Dentin Matrix for Dental Tissue Regeneration.
Melling GE, Colombo JS, Avery SJ, Ayre WN, Evans SL, Waddington RJ, Sloan AJ.Tissue Eng Part A. 2018 Feb 21. doi: 10.1089/ten.TEA.2017.0419. PMID: 29316874
Acellular (UKRMP1)
Returned 150 item(s)